All solutions related to medical cannabis require action by Congress

All solutions related to medical cannabis require action by Congress

Presently, more than 300 million people in America are living in states lacking medical cannabis laws, and more than 2 million people have been legally using medical cannabis as part of state programs. However, all such patients and programs have been violating federal laws.

In the last some years, nearly all federal interference has stopped (over $500,000,000 dollars of anti-medical cannabis federal enforcement later) because of the route taken by the Rohrabacher-Farr medical cannabis amendment to the CJS appropriations bill in 2014 and last year, banning federal intrusion in state medical cannabis programs and the August 2013 Department of Justice memo, clarifying that state legal medical marijuana isn’t a main priority for federal enforcement.

In the past one week, thecountry has once again focused on the federal fight between the states and federal government as it connects with medical cannabis, and every solution demands Congress’ action.

The Drug Enforcement Administration (DEA) made an announcement on August 10 that they have declined a petition of cannabis removal from the most limiting Schedule 1 category, saying that the decision mainly relied on the determination of the FDA regarding whether marijuana is ‘a safe and effective medicine’ or not.

The same day, the DEA came up with two other memos, first one stated that they would be licensing extra entities for growing cannabis for research studies, and secondly provide direction to the industrial hemp industry.

The DEA’s announcements were probably a mixed bag, but on August 16, the federal 9th Circuit decided by a three-judge panel came up with an opinion that was a key victory.

The 9th Circuit Judge Diarmuid F. O’Scannlain wrote U.S. vs. McIntosh, wherein the court said that the Rohrabacher-Farr Amendment bans the federal prosecution of conduct that is legal as per the state medical cannabis law.